(Q44454004)

3 December 2017

title

A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up (English)

1 reference

3 December 2017

main subject

phase III clinical trial

0 references

1 reference

9

Eva Singletary

1 reference

3 December 2017

2

Aman Buzdar

1 reference

3 December 2017

Vasily Assikis

1

1 reference

3 December 2017

Ying Yang

3

1 reference

3 December 2017

Terry Smith

4

1 reference

3 December 2017

Richard Theriault

5

1 reference

3 December 2017

Daniel Booser

6

1 reference

3 December 2017

Vicente Valero

7

1 reference

3 December 2017

Ronald Walters

8

1 reference

3 December 2017

Frederick Ames

10

1 reference

3 December 2017

Gabriel Hortobagyi

11

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

97

1 reference

3 December 2017

issue

11

1 reference

3 December 2017

page(s)

2716-2723

1 reference

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11396

7 January 2021

Identifiers

DOI

10.1002/CNCR.11396

1 reference

3 December 2017

1 reference